Gilead Sciences to Acquire Ouro Medicines for $2.2 Billion, Bolstering Autoimmune Portfolio.

Gilead Sciences has agreed to acquire privately-held biotechnology company Ouro Medicines for $2.18 billion. The deal aims to bolster Gilead's autoimmune portfolio with Ouro's lead clinical-stage drug candidate. Gilead is betting on the potential of "immune reset" therapies, which aim to reprogram the immune system to treat autoimmune diseases. The acquisition is seen as a strategic move to enhance Gilead's position in the autoimmune space.